AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05600790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress
Description: Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
Study NCT03994497 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood samples the day of the surgery and 4 times during the next year. Blood samples and histological slides taken at each biopsy and if there is suspicion of rejection of the graft
Study NCT06280547 — intervention group
Intervention type: OTHER
Intervention: Oral health education
Description: Oral Health Education Program performed in the school.
Study NCT06145386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise and Strength Training
Description: Aerobic Exercise and Strength Training on Physical Activity Level, Quality of Life and Anxiety-Stress Disorder in Young Adults With and Without Covid-19
Study NCT05110716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bundle-size 1
Description: In this condition, each choice in the adjusting-amount task produces only a single consequence (e.g., lose $900 in 1 year).
Study NCT05644353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC.
Study NCT05110716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bundle-size 3
Description: In this condition, each choice in the adjusting-amount task produce a series of three consequences over time. o hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series. (e.g., lose $300 in 1 year, lose $300 in 2 years, lose $300 in 3 years).
Study NCT05110716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bundle-size 9
Description: In this condition, each choice in the adjusting-amount task produce a series of nine consequences over time. To hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series. (e.g., lose $100 in 1 year, lose $100 in 2 years, lose $100 in 3 years...lose $100 in 9 years).
Study NCT06283394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storefront Choice Architecture
Description: An Instacart storefront with choice architecture manipulation (healthy items for diabetics appear first and less healthy items are less visible)
Study NCT06283394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fresh Funds
Description: The treatment groups will each receive a $160 subsidy per month for 3 months to be used on produce through Instacart.
Study NCT06283394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Framing
Description: They will receive text messages detailing how much of their $160 subsidy is left (beginning of weeks 1, 2, 3, and 4 and following end of the month).
Study NCT05903456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE（transcatheter arterial chemoembolization）
Description: TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor.
Study NCT05903456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Ronvastinib is an orally administered multi-receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activity of vascular endothelial growth factor (VEGF) receptors, such as VEGF-1, VEGF-2, and VEGF-3, in addition to inhibiting other pro-angiogenic and oncogenic signaling pathways associated with tumor proliferation ，has been approved as a first-line treatment for liver cancer
Study NCT05903456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icaritin soft capsules
Description: Icaritin soft capsule is a flavonoid compound extracted from traditional Chinese medicinal materials. It is a new type of small molecule immunomodulator. It is a 1.2 class of innovative Chinese medicine with global independent intellectual property rights. By inhibiting inflammatory signaling pathway and reducing the release of inflammatory factors, the immune microenvironment can be regulated to play an anti-tumor role. At present, it has been approved for first-line treatment of advanced liver cancer, with good efficacy and safety.
Study NCT05596474 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beet-root juice
Description: Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a 400mg nitrate once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third 400mg dose of nitrates at least 150 minutes before forearm endurance testing.
Study NCT05596474 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Beet-root juice
Description: Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a 400mg nitrate once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third 400mg dose of nitrates at least 150 minutes before forearm endurance testing.
Study NCT05596474 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: red-light therapy
Description: Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to 660nm wave length light for 10-minutes.
Study NCT05596474 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: red-light therapy
Description: Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to 660nm wave length light for 10-minutes.
Study NCT05596474 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a nitrate depleted placebo once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third dose of the nitrate depleted placebo at least 150 minutes before forearm endurance testing.
Study NCT05596474 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a nitrate depleted placebo once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third dose of the nitrate depleted placebo at least 150 minutes before forearm endurance testing.
Study NCT05596474 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: sham light
Description: Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to sham light for 10-minutes.
Study NCT05596474 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: sham light
Description: Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to sham light for 10-minutes.
Study NCT04312789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Given PO
Study NCT05412667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TWK10
Description: 1. 4 days without training: drink 2 hours before bedtime.~2. 3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~3. To analyze the amino acid concentration in blood, drink it immediately before blood collection.
Study NCT05412667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. 4 days without training: drink 2 hours before bedtime.~2. 3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~3. To analyze the amino acid concentration in blood, drink it immediately before blood collection.
Study NCT06507137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fractal
Description: Walking in a treadmill while synchronizing their steps with fractal external visual cues
Study NCT06507137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isochronous
Description: Walking in a treadmill while synchronizing their steps with isochronous external visual cues
Study NCT05532124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAENNEC (Human Placenta Hydrolysate)
Description: Intravenous Injection
Study NCT05532124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: Intravenous Injection
Study NCT06507137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Walking in a treadmill
Study NCT05801172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ketoprofen for pain relief in office hysteroscopy
Description: ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy
Study NCT05801172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ketoprofen plus infiltration anesthesia with lidocaine for pain relief in office hysteroscopy
Description: ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in intracervical administration at the start of the procedure
Study NCT05801172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ketoprofen plus paracervical block anesthesia with lidocaine for pain relief in office hysteroscopy
Description: ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in paracervical block at the start of the procedure
Study NCT04994522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Three 40 mg tablets given as a single oral 120 mg dose.
Study NCT05341193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab
Description: Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy.
Study NCT05341193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab
Description: Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy.
Study NCT05154578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2 Vaccine
Description: 0.5 mL GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS-NN2 and 0.5 mg of aluminium, given by intramuscular injection.
Study NCT05545371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immunization procedures
Description: The subjects were vaccinated with rabies vaccine according to different immunization procedures
Study NCT04478630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract
Description: Inhaled Aromatherapy via a pocket sized diffuser which contains one of the following:Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract (placebo-control).
Study NCT04478630 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract
Description: Inhaled Aromatherapy via a pocket sized diffuser which contains one of the following:Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract (placebo-control).
Study NCT04720131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab was administered 200mg iv every 3 weeks.
Study NCT04720131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Apatinib A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle) The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group.~The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage.
Study NCT04720131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle)
Study NCT04616547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04616547 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tin Sn 117m Pentetate
Description: Given IV
Study NCT05154578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL normal saline given by intramuscular injection
Study NCT05154578 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL normal saline given by intramuscular injection
Study NCT05299138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marriage and Relationship Enhancement Skills (MRES) Intervention
Description: The Intervention group will be assigned a Case Manager and placed in the next available Marriage and Relationship Enhancement Skills (MRES) class that is convenient for their schedule. Intervention participants will attend classes weekly and meet with their Case Manager weekly, bi-weekly, or monthly, as needed. Study measures will be gathered from intervention participants at baseline, 10 weeks after baseline, and then 22 weeks after baseline. The following tools will be utilized at baseline and follow-up assessment: (1) REACH program eligibility screening (only conducted at baseline), (2) Information, Family Outcomes, Reporting, and Management (nFORM) system, (3) Family Environment Scale (FES), (4) Revised Dyadic Adjustment Scale (RDAS), and (5) Economic Self-Sufficiency Scale (ESS).
Study NCT05826041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: (INSPIRE) INtervention Support groups: Peers Inspiring Resilience and Empowerment.
Description: The support group contains both structured components, which are psychoeducational and focused on skill-building, and an unstructured component where discussion is open and determined by the needs and interests of the clients present (e.g., support and process-oriented.)
Study NCT05826041 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Domestic Violence Support Group
Description: The activities of the group are determined by agency staff from week to week and may be open group discussion, psychoeducation, or a combination of both.
Study NCT06632314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral feeding
Description: Enteral feeding will be withheld or continued in very low birthweight neonates during packed red blood cell transfusion. Regional cerebral and splanchnic oxygenation will be measured using near-infrared spectroscopy (NIRS) for 48 hours. Cerebral and splanchnic oxygenation parameters, including cerebral regional oxygen saturation (crSO2), splanchnic regional oxygen saturation (srSO2), the ratio of crSO2 to srSO2 (CSOR), cerebral fractionated tissue oxygen saturation (cFTOE) and splanchnic fractionated tissue oxygen saturation (sFTOE) will be measured immediately before PRBCT (baseline) and at the first, sixth, 12th, 24th, and 48th hours after PRBCT using near-infrared spectroscopy.
Study NCT06633146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapies in nature
Description: Therapeutic tasks in nature specifically designed for the study
Study NCT06633731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biocellulose Mask
Description: Immediately after treatment, a Biocellulose Mask was applied to the subjects global face for 8 to 10 minutes.
Study NCT06633731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Procedure Cream
Description: Immediately after treatment and after Biocellulose Mask removal, the Post-Procedure Cream was applied to the subjects global face. Subjects were instructed to apply to the global face from days 1 - 3 post treatment.
Study NCT05182541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided self help
Description: Introduce the knowledge about twins pregnancy, and reduce the pregnant stress, and relief the anxiety and depressor.
Study NCT05182541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem solving therapy
Description: Based on the steps of problem-solving therapy, nurses guide mothers with mild psychological problems to solve the existing problems through wechat and telephone, 10-15 min each time for 4 weeks
Study NCT05182541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face to face PST course
Description: Face to face interviews with nurses with psychological counselors, combined with auxiliary tools, identify patients' problems, set goals for patients, provide different solutions, and let patients choose appropriate ways according to their preferences. Once a week, 1 hour for the first time and 45 min for the rest for 5 weeks.
Study NCT05182541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Professional psychological intervention
Description: The mental health physicians and (or) psychological counselors strengthened the intervention and carried out specialized nursing
Study NCT04974268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific supervised exercise and weight loss program
Description: Intervention group that receives supervised exercise and weight loss program based on individual and group intervention with Mediterranean diet and substitute for a daily meal, manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
Study NCT06633731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gentle Cleanser
Description: Subjects were instructed to wash their face with the Gentle Foaming Cleanser twice daily for 12 weeks.
Study NCT06633731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Moisturizer
Description: Subjects were instructed to apply the facial moisturizer twice daily to the global face from day 3 after treatment until next study visit.
Study NCT06633731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sunscreen
Description: Subjects were instructed to apply the bland sunscreen to the global face once daily in the morning, with re-application with extended sun exposure per FDA guidelines.
Study NCT06632522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radiotherapy combined with Camrelizumab and Apatinib
Description: Camrelizumab is administered intravenously (without preventive medication), with a fixed dose of 200mg, with an infusion of 30 min (not less than 20 min and not more than 60 min) every three weeks. Apatinib, 250 mg, taken orally within half an hour after meals, QD, continuously.
Study NCT05117268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SDF Application for caries arrest
Description: Intervention will be performed by trained consultants following the recommended protocol for SDF application: (A) Gross debris will be removed from cavity to allow better contact with SDF; (B) Protective coating of petroleum jelly will be applied to surrounding facial skin and lips to prevent chances of temporary tattoo formation; (C) Area to be treated shall be isolated using cotton rolls and saliva ejectors to prevent gingival irritation; (D) Extra caution will be exercised when applying SDF on primary teeth adjacent to permanent teeth to avoid inadvertent black staining; (E) One drop will be used used for the whole appointment. Bent micro-brush is to be used for application time of 1 min is to be used to reduce systemic absorption; (F) Compressed air shall be applied with gentle flow for up to 3 minutes. Entire dentition will be treated with sodium fluoride varnish to prevent caries
Study NCT05246670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palmidrol
Description: Given PEA PO
Study NCT05246670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT05246670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies